Does the media prefer TWST or DNA?

In the previous week, Twist Bioscience had 23 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 25 mentions for Twist Bioscience and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.47 beat Twist Bioscience's score of 0.44 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 11 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is DNA or FTRE more profitable?

Fortrea has a net margin of -3.18% compared to Ginkgo Bioworks' net margin of -259.96%. Fortrea's return on equity of 10.72% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -259.96% -60.27% -26.88% Fortrea -3.18% 10.72% 2.17%

Does the media refer more to DNA or FTRE?

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 2 articles in the media. Ginkgo Bioworks' average media sentiment score of 0.47 beat Fortrea's score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Fortrea 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DNA or MRVI?

In the previous week, Maravai LifeSciences had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 4 mentions for Maravai LifeSciences and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.47 beat Maravai LifeSciences' score of 0.31 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to DNA or BLFS?

In the previous week, BioLife Solutions had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for BioLife Solutions and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.47 beat BioLife Solutions' score of 0.34 indicating that Ginkgo Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioLife Solutions 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PSNL or DNA more profitable?

Personalis has a net margin of -153.84% compared to Ginkgo Bioworks' net margin of -259.96%. Personalis' return on equity of -46.47% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Personalis -153.84% -46.47% -35.30% Ginkgo Bioworks -259.96% -60.27% -26.88%

Does the media prefer PSNL or DNA?

In the previous week, Personalis had 12 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 14 mentions for Personalis and 2 mentions for Ginkgo Bioworks. Personalis' average media sentiment score of 0.58 beat Ginkgo Bioworks' score of 0.47 indicating that Personalis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Ginkgo Bioworks (DNA) Competitors

$10.30 +1.72 (+20.07%)

Closing price 03:59 PM Eastern

Extended Trading

$10.22 -0.09 (-0.83%)

As of 07:59 PM Eastern

Compare

DNA vs. TWST, FTRE, MRVI, BLFS, and PSNL

Should you buy Ginkgo Bioworks stock or one of its competitors? Ginkgo Bioworks's main competitors and comparable companies include Twist Bioscience (TWST), Fortrea (FTRE), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), and Personalis (PSNL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Ginkgo Bioworks compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Ginkgo Bioworks (NYSE:DNA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Twist Bioscience has a beta of 2.22, meaning that its stock price is 122% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Twist Bioscience has a net margin of -31.66% compared to Ginkgo Bioworks' net margin of -259.96%. Twist Bioscience's return on equity of -28.64% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

In the previous week, Twist Bioscience had 23 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 25 mentions for Twist Bioscience and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.47 beat Twist Bioscience's score of 0.44 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	11 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	30.65	-$77.67M	-$2.22	N/A
Ginkgo Bioworks	$170.15M	4.08	-$312.76M	-$5.01	N/A

78.6% of Ginkgo Bioworks shares are held by institutional investors. 3.1% of Twist Bioscience shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Twist Bioscience currently has a consensus price target of $103.00, suggesting a potential downside of 44.03%. Ginkgo Bioworks has a consensus price target of $6.33, suggesting a potential downside of 38.52%. Given Ginkgo Bioworks' higher possible upside, analysts clearly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Twist Bioscience beats Ginkgo Bioworks on 11 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Fortrea?

Ginkgo Bioworks (NYSE:DNA) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 0.7% of Fortrea shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Ginkgo Bioworks presently has a consensus price target of $6.33, indicating a potential downside of 38.52%. Fortrea has a consensus price target of $22.00, indicating a potential upside of 9.89%. Given Fortrea's stronger consensus rating and higher probable upside, analysts plainly believe Fortrea is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Fortrea has a net margin of -3.18% compared to Ginkgo Bioworks' net margin of -259.96%. Fortrea's return on equity of 10.72% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Fortrea	-3.18%	10.72%	2.17%

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 2 articles in the media. Ginkgo Bioworks' average media sentiment score of 0.47 beat Fortrea's score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fortrea	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ginkgo Bioworks has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Fortrea has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

Ginkgo Bioworks has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	4.08	-$312.76M	-$5.01	N/A
Fortrea	$2.72B	0.70	-$986.20M	-$0.91	N/A

Summary

Fortrea beats Ginkgo Bioworks on 9 of the 14 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Maravai LifeSciences?

Ginkgo Bioworks (NYSE:DNA) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Maravai LifeSciences has a net margin of -37.07% compared to Ginkgo Bioworks' net margin of -259.96%. Maravai LifeSciences' return on equity of -15.70% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
Maravai LifeSciences	-37.07%	-15.70%	-8.17%

In the previous week, Maravai LifeSciences had 2 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 4 mentions for Maravai LifeSciences and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.47 beat Maravai LifeSciences' score of 0.31 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Ginkgo Bioworks has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

Ginkgo Bioworks presently has a consensus price target of $6.33, indicating a potential downside of 38.52%. Maravai LifeSciences has a consensus price target of $6.83, indicating a potential downside of 10.68%. Given Maravai LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Maravai LifeSciences has higher revenue and earnings than Ginkgo Bioworks. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	4.08	-$312.76M	-$5.01	N/A
Maravai LifeSciences	$185.74M	10.69	-$130.77M	-$0.52	N/A

Summary

Maravai LifeSciences beats Ginkgo Bioworks on 11 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to BioLife Solutions?

Ginkgo Bioworks (NYSE:DNA) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

In the previous week, BioLife Solutions had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for BioLife Solutions and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.47 beat BioLife Solutions' score of 0.34 indicating that Ginkgo Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioLife Solutions	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioLife Solutions has a net margin of 53.29% compared to Ginkgo Bioworks' net margin of -259.96%. BioLife Solutions' return on equity of 2.70% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
BioLife Solutions	53.29%	2.70%	2.49%

BioLife Solutions has lower revenue, but higher earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	4.08	-$312.76M	-$5.01	N/A
BioLife Solutions	$96.21M	19.62	-$4.59M	$1.16	33.26

Ginkgo Bioworks has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

Ginkgo Bioworks currently has a consensus target price of $6.33, indicating a potential downside of 38.52%. BioLife Solutions has a consensus target price of $31.38, indicating a potential downside of 18.68%. Given BioLife Solutions' stronger consensus rating and higher probable upside, analysts plainly believe BioLife Solutions is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioLife Solutions	0 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.09

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

BioLife Solutions beats Ginkgo Bioworks on 12 of the 15 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Personalis?

Personalis (NASDAQ:PSNL) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Personalis presently has a consensus target price of $14.54, suggesting a potential downside of 12.28%. Ginkgo Bioworks has a consensus target price of $6.33, suggesting a potential downside of 38.52%. Given Personalis' stronger consensus rating and higher possible upside, research analysts plainly believe Personalis is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Personalis has higher earnings, but lower revenue than Ginkgo Bioworks. Personalis is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	24.91	-$81.27M	-$1.09	N/A
Ginkgo Bioworks	$170.15M	4.08	-$312.76M	-$5.01	N/A

In the previous week, Personalis had 12 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 14 mentions for Personalis and 2 mentions for Ginkgo Bioworks. Personalis' average media sentiment score of 0.58 beat Ginkgo Bioworks' score of 0.47 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Personalis has a net margin of -153.84% compared to Ginkgo Bioworks' net margin of -259.96%. Personalis' return on equity of -46.47% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%

Personalis has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.76, suggesting that its share price is 76% more volatile than the broader market.

61.9% of Personalis shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Personalis beats Ginkgo Bioworks on 11 of the 15 factors compared between the two stocks.

Get Ginkgo Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNA vs. The Competition

Export

Metric	Ginkgo Bioworks	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$630.98M	$10.80B	$7.26B	$22.83B
Dividend Yield	N/A	1.45%	2.52%	3.63%
P/E Ratio	N/A	75.66	274.98	27.94
Price / Sales	4.08	282.99	679.25	85.19
Price / Cash	N/A	27.90	77.80	38.70
Price / Book	1.18	6.06	10.52	4.65
Net Income	-$312.76M	$56.67B	$3.49B	$1.07B
7 Day Performance	31.20%	3.74%	-1.08%	-1.85%
1 Month Performance	51.83%	4.13%	-3.39%	-5.27%
1 Year Performance	-10.92%	37.40%	15.08%	6.83%

Ginkgo Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNA Ginkgo Bioworks	1.1463 of 5 stars	$10.30 +20.1%	$6.33 -38.5%	-30.5%	$630.98M	$170.15M	N/A	485	High Trading Volume
TWST Twist Bioscience	1.3105 of 5 stars	$165.83 -0.7%	$103.00 -37.9%	+473.4%	$10.47B	$376.57M	N/A	979	Trending News Analyst Forecast Insider Trade
FTRE Fortrea	2.221 of 5 stars	$20.02 +0.5%	$22.00 +9.9%	+108.3%	$1.90B	$2.72B	N/A	14,300
MRVI Maravai LifeSciences	1.1997 of 5 stars	$7.17 +2.9%	$6.83 -4.7%	+169.0%	$1.81B	$185.74M	N/A	415	Positive News
BLFS BioLife Solutions	2.3804 of 5 stars	$37.18 +1.3%	$31.38 -15.6%	+52.5%	$1.79B	$106.69M	32.05	155	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DNA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, FTRE, MRVI, BLFS, and PSNL

How does Ginkgo Bioworks compare to Twist Bioscience?

Summary

How does Ginkgo Bioworks compare to Fortrea?

Summary

How does Ginkgo Bioworks compare to Maravai LifeSciences?

Summary

How does Ginkgo Bioworks compare to BioLife Solutions?

Summary

How does Ginkgo Bioworks compare to Personalis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, FTRE, MRVI, BLFS, and PSNL

How does Ginkgo Bioworks compare to Twist Bioscience?

Which has more risk and volatility, TWST or DNA?

Is TWST or DNA more profitable?

Does the media prefer TWST or DNA?

Which has better earnings & valuation, TWST or DNA?

Do insiders and institutionals have more ownership in TWST or DNA?

Do analysts recommend TWST or DNA?

Summary

How does Ginkgo Bioworks compare to Fortrea?

Do institutionals & insiders believe in DNA or FTRE?

Do analysts prefer DNA or FTRE?

Is DNA or FTRE more profitable?

Does the media refer more to DNA or FTRE?

Which has more volatility & risk, DNA or FTRE?

Which has preferable earnings & valuation, DNA or FTRE?

Summary

How does Ginkgo Bioworks compare to Maravai LifeSciences?

Is DNA or MRVI more profitable?

Does the media refer more to DNA or MRVI?

Do insiders and institutionals believe in DNA or MRVI?

Which has more risk & volatility, DNA or MRVI?

Do analysts prefer DNA or MRVI?

Which has better earnings and valuation, DNA or MRVI?

Summary

How does Ginkgo Bioworks compare to BioLife Solutions?

Does the media refer more to DNA or BLFS?

Is DNA or BLFS more profitable?

Which has higher valuation and earnings, DNA or BLFS?

Which has more risk and volatility, DNA or BLFS?

Do analysts prefer DNA or BLFS?

Do institutionals & insiders believe in DNA or BLFS?

Summary

How does Ginkgo Bioworks compare to Personalis?

Do analysts rate PSNL or DNA?

Which has higher valuation & earnings, PSNL or DNA?

Does the media prefer PSNL or DNA?

Is PSNL or DNA more profitable?

Which has more risk and volatility, PSNL or DNA?

Do institutionals and insiders hold more shares of PSNL or DNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools